autologous anti-BCMA-CAR-4-1BB-CD3zeta-expressing CD4+/CD8+ T lymphocytes JCARH125

{
  "id": "MLC-T-ONC-011339",
  "term": "autologous anti-BCMA-CAR-4-1BB-CD3zeta-expressing CD4+/CD8+ T lymphocytes JCARH125",
  "field": "Oncology and biomedicine",
  "definition": "A preparation of autologous CD4- and CD8-positive T lymphocytes that have been ex vivo transduced with a genetically-engineered lentiviral vector (LV) expressing a chimeric antigen receptor (CAR) containing a single chain variable fragment (scFv) specific for the tumor-associated antigen (TAA) human B-cell maturation antigen (BCMA; tumor necrosis factor receptor superfamily member 17; TNFRSF17) fused to the co-stimulatory domain of 4-1BB (CD137) and the CD3-zeta (CD3z) T-cell signaling domain, with potential immunostimulating and antineoplastic activities. Upon administration, autologous anti-BCMA-CAR-4-1BB-CD3zeta-expressing CD4+/CD8+ T lymphocytes JCARH125 specifically recognize and induce selective toxicity in BCMA-expressing tumor cells. BCMA, a tumor-specific antigen and a receptor for both a proliferation-inducing ligand (APRIL) and B-cell activating factor (BAFF), is a member of the tumor necrosis factor receptor superfamily (TNFRSF) and plays a key role in plasma cell survival. BCMA is found on the surfaces of plasma cells and overexpressed on malignant plasma cells.",
  "synonyms": [
    "autologous anti-BCMA CAR-T cells JCARH 125",
    "autologous BCMA-specific CAR-T cells JCARH125",
    "autologous BCMA 41BBz CAR-T cells JCARH-125",
    "autologous BCMA-specific CAR4-1BB-CD3zeta-expressing CD4+/CD8+ T lymphocytes JCARH 125"
  ],
  "references": [
    "National Cancer Institute Thesaurus"
  ],
  "url": "https://mlchart.com/terminology/oncology/autologous-anti-bcma-car-4-1bb-cd3zeta-expressing-cd4-plus-cd8-plus-t-jcarh125/"
}